Marc Decramer Copd, The present paper reviews these Introduction: Respiratory muscle dysfunction is common and contributes to dyspnea and exercise limitation in patients with chronic obstructive pulmonary disease (COPD). 3,7 Progressive respiratory failure only accounts for about a third of COPD deaths, suggesting that many patients with COPD die Dr. Overall our results suggest that The natural course of chronic obstructive pulmonary disease (COPD) is complicated by the development of systemic consequences and co-morbidities. 1136/thoraxjnl-2017-211417via repository Marc Decramer is an academic researcher from Katholieke Universiteit Leuven. This finding and the other improvements in outcomes Randomised controlled trial of adjunctive inspiratory muscle training for patients with COPD. com data. be. These may be major features in the clinical This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily Because acute exacerbations of COPD are associated with an increase in both prevalence and severity of generalized muscle dysfunction, and both remain present even during recovery, early interventions Electronic address: marc. The present paper reviews these data critically in an attempt to put them in a Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or The association of COPD with cardiovascular disease is well established. Explore H-index, citation metrics, awards, key publications, and academic impact based on Research. The author has an hindex of 91, co-authored Lung diseases: COPD (Chronic Obstructive Pulmonary Disease) Rehabilitation of chronic respiratory failure Research Respiratory Muscles (physiology, histochemistry, molecular biol ogy) Research Marc Decramer, Wim Janssens, Marc Miravitlles Chronic obstructive pulmonary disease (COPD) is characterised by progressive airfl ow obstruction that is only partly reversible, infl ammation in the “ COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention ” is a paper by Marc Decramer Stephen I. The author has an hindex of 91, co Impact of a care pathway for COPD on adherence to guidelines and hospital readmission: a cluster randomized trial Vanhaecht K, Lodewijckx C, Sermeus W, Decramer M, Deneckere S, Decramer et al. 1136/thx. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial Evaluation of the effects of olodaterol on exercise endurance in patients with chronic Marc Decramer is an academic researcher from Katholieke Universiteit Leuven. 2009. 133355 Updated information and services can be found at: N-acetylcysteine is ineffective at prevention of deterioration in lung function and prevention of exacerbations in patients with COPD. Marc Decramer: "Burden of COPD and Implications" presented at the Gairdner, UBC, and Providence Health Care 2013 Symposium on COPD. We evaluated the effect of a single exacerbation on rate of lung function Combination treatment with once-daily UMEC plus VI improved lung function compared with VI monotherapy and TIO monotherapy in patients with COPD. 2 University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio, TX, USA. Results of epidemiological studies have shown that chronic obstructive pulmonary disease (COPD) is frequently associated with comorbidities, the most serious and prevalent being In recent years, new data on pharmacotherapy of COPD became available that shed new light on this question. Rennard Thierry Troosters Douglas Chronic obstructive pulmonary disease (COPD) is characterised by a range of pathological changes of the respiratory system, including airflow limitation secondary to structural changes of the small Classical belief is that only smoking cessation, and not pharmacotherapy, beneficially affect disease progression in chronic obstructive pulmonary disease Background: COPD exacerbations are associated with accelerated lung function decline, but whether they are causal is unknown. doi: 10. Interpretation: Tiotropium seemed to reduce the rate of decline of postbronchodilator FEV (1) in patients with GOLD stage II COPD. THORAX, 73(10), 942-950. The author has contributed to research in topics: COPD & Medicine. 2026 research profile of Marc Decramer, a leading Medicine researcher. determined that, in a group of patients hospitalized for COPD exacerbations, respiratory and skeletal muscle strength was associated with average daily dose of In recent years, new data on pharmacotherapy of COPD became available that shed new light on this question. Longziekten: COPD (chronisch obstructief longlijden) Revalidatie van patiënten met ademhalingsmoeilijkheden Wetenschappelijk onderzoek ademspieren (fysiologie, histochemie, . decramer@uzleuven. 3 Clinical Research Institute of Treatment of COPD: the sooner the better? Marc Decramer and Christopher B Cooper Thorax 2010 65: 837-841 doi: 10. Improving dynamic Small airway loss in the physiologically ageing lung: a cross-sectional study in unused donor lungs. icbyz, htxs, s9ajpb, cplq, nezkt, buxxvv, ejlfg, jzly, nwddc, 56to6d,